+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rheumatoid Arthritis - Epidemiology Forecast to 2029

  • ID: 5212224
  • Report
  • November 2020
  • Region: Global
  • 46 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Rheumatoid Arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. The condition manifests itself in multiple joints in the body (Mayo Clinic, 2019; Centers for Disease Control and Prevention, 2020). RA is the result of an immune response in which the body’s immune system attacks its own healthy cells, especially the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response (Centers for Disease Control and Prevention, 2020). The disease can lead to premature mortality, disability, and decreased quality of life due to bone erosion and joint deformity (Brooks, 2006; Centers for Disease Control and Prevention, 2020).

The publisher's epidemiologists utilized county-specific studies published in peer-reviewed journals to build the forecast. The publisher's epidemiologists used sources that confirmed RA cases based on the American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06, in order to ensure a uniform case definition across markets. The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent (total and diagnosed) cases of RA in the 8MM, segmented by age, sex, and severity.

The following data describes epidemiology of RA. In the 8MM, the publisher's epidemiologists forecast an increase in the diagnosed incident cases of RA from 389,747 cases in 2019 to 425,455 cases in 2029, at an AGR of 0.92% over the forecast period. The diagnosed prevalent cases of RA in the 8MM will increase from 4,605,338 cases in 2019 to 5,093,229 cases in 2029, at an AGR of 1.06% over the forecast period. The total prevalent cases of RA in the 8MM will increase from 6,308,268 cases in 2019 to 6,980,823 cases in 2029, at an AGR of 1.07% over the forecast period. RA is more common in women, and the incidence and prevalence of RA typically increases with advancing age. These trends are reflected in the publisher’s forecast for the diagnosed incident and prevalent (total and diagnosed) cases for the 8MM.

Scope
  • The Rheumatoid Arthritis (RA) Epidemiology Report provides an overview of the risk factors and global trends of IPF in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent cases of RA (total and diagnosed) segmented by sex and age (ages ≥18 years). The prevalent cases of RA (total and diagnosed) are also segmented by severity (mild, moderate, and severe). In addition, the model corresponding to this report includes prevalent cases of RA (total and diagnosed) segmented by comorbidities (depression, cardiovascular disease, cancer, gastrointestinal ulcer, hypertension, hyperlipidemia, obesity, osteoporosis, osteoarthritis, chronic obstructive pulmonary disease, and asthma).
  • The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to Buy

The Rheumatoid Arthritis Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global RA market.
  • Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RA therapeutics in each of the markets covered.
  • Understand magnitude of RA population by severity at diagnosis.
Note: Product cover images may vary from those shown
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for RA (2019-2029)
3.5.1 Diagnosed Incident Cases of RA
3.5.2 Sex-Specific Diagnosed Incident Cases of RA
3.5.3 Age-Specific Diagnosed Incident Cases of RA
3.5.4 Diagnosed Prevalent Cases of RA
3.5.5 Sex-Specific Diagnosed Prevalent Cases of RA
3.5.6 Age-Specific Diagnosed Prevalent Cases of RA
3.5.7 Diagnosed Prevalent Cases of RA by Severity
3.5.8 Total Prevalent Cases of RA
3.5.9 Sex-Specific Total Prevalent Cases of RA
3.5.10 Age-Specific Total Prevalent Cases of RA
3.5.11 Total Prevalent Cases of RA by Severity
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4 Appendix
4.1 Bibliography
4.2 Primary Research - KOLs Interviewed for this Report
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About the Publisher
4.5 Contact
4.6 Disclaimer

List of Tables
Table 1: Summary of Updated Data Types
Table 2: Risk Factors and Comorbidities for RA

List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019 and 2029
Figure 2: 8MM, Diagnosed Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019 and 2029
Figure 3: 8MM, Diagnosed Incidence of RA (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2019
Figure 4: 8MM, Diagnosed Prevalence (%) of RA, Both Sexes, Ages ≥18 Years, 2019
Figure 5: 8MM, Total Prevalence (%) of RA, Both Sexes, Ages ≥18 Years, 2019
Figure 6: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of RA
Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed and Total Prevalent Cases of RA
Figure 8: 8MM, Diagnosed Incident Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019
Figure 9: 8MM, Diagnosed Incident Cases of RA, N, by Sex, Ages ≥18 Years, 2019
Figure 10: 8MM, Diagnosed Incident Cases of RA by Age, N, Both Sexes, 2019
Figure 11: 8MM, Diagnosed Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019
Figure 12: 8MM, Diagnosed Prevalent Cases of RA, N, by Sex, Ages ≥18 Years, 2019
Figure 13: 8MM, Diagnosed Prevalent Cases of RA by Age, N, Both Sexes, 2019
Figure 14: 8MM, Diagnosed Prevalent Cases of RA by Severity, N, Both Sexes, Ages ≥18 Years, 2019
Figure 15: 8MM, Total Prevalent Cases of RA, N, Both Sexes, Ages ≥18 Years, 2019
Figure 16: 8MM, Total Prevalent Cases of RA, N, by Sex, Ages ≥18 Years, 2019
Figure 17: 8MM, Total Prevalent Cases of RA by Age, N, Both Sexes, 2019
Figure 18: 8MM, Total Prevalent Cases of RA by Severity, N, Both Sexes, Ages ≥18 Years, 2019
Note: Product cover images may vary from those shown
Adroll
adroll